Shares of French biotech Abivax tumbled as a lot 32% after it reported contemporary information on its lead asset, a drug for ulcerative colitis.
The medication met its endpoints of demonstrating a clinically significant efficacy and a remission fee of about 40% for each doses examined, but in addition confirmed that there have been most cancers instances amongst sufferers taking the upper dose.
“[The] most cancers sign complicates issues,” a Jefferies analyst mentioned. “Even when unrelated noise, we predict the overhang might be actual, particularly contemplating absence of different value-inflecting information occasions over the subsequent [year].”
Within the research cohort, there was one reported case every of prostate most cancers, breast most cancers, and colonic dysplasia, which Abivax mentioned have been unrelated to therapy.
There have been additionally 4 instances of pores and skin most cancers on the upper 50 mg dose, of which two have been deemed not or unlikely associated to the drug, and the opposite two had a medical historical past of pores and skin most cancers, Abivax mentioned.
The Jefferies analysts mentioned that “an affordable clarification” for the most cancers instances was believable, however “does not seem to be an simply dismissed overhang.”
The inventory gained almost 1,700% in 2025, however shares had fallen 7% coming into Tuesday buying and selling. It was final buying and selling down over 32%.
Abivax shares year-to-date.
The trial outcomes, revealed late Monday, have been from a upkeep research by which Abivax assessed the impact of the drug, obefazimod, over 44 weeks. It comes after the outcomes of a late-stage trial for an ulcerative colitis medication in mid-2025, beating even essentially the most optimistic expectations.
Analysts have described the experimental drug as a possible best-in-class therapy for ulcerative colitis. Abivax can be testing the medication for Crohn’s illness, opening it as much as a multi-billion-dollar marketplace for Irritable Bowel Syndrome (IBS).
“The 44-week upkeep information reveal obefazimod’s potential to ship significant efficacy and sturdy illness management in ulcerative colitis,” mentioned Abivax’s David Rubin, additionally director of the inflammatory bowel illness middle on the College of Chicago Medication.
“The novel mechanism, sustained scientific remission, and favorable long-term security profile spotlight its potential to handle a major unmet want in UC.”
The corporate has been positioned as a chief takeover goal, with unconfirmed rumors that massive pharma has its eyes on the clinical-stage biotech led by CEO Marc de Garidel.
De Garidel informed CNBC in March that he was assured the upkeep research would learn out positively, and signaled that the corporate was in no rush to safe a deal or a partnership, as phrases can be higher after it.
It has been extensively anticipated that Abivax can be acquired earlier than launching obefazimod, and de Garidel informed CNBC that it was planning to lift cash after the June information readout.
